It's certainly taken longer than I expected but everytime we get an update, in my opinion, things look even better. From the 2023 ASCO Mechanism of Action talk we learned that DCVax can target many different diseases. So management must get this first approval right given the many millions who could benefit from this technology.
I have made a modest paper profit on this stock because I purchased a lot in the $0.30s but my buys above $1 as well as $0.60 have raised my cost basis a lot. My wife has been upset, yet patient, as have others who I informed about this stock.
I did not buy this company in 2020 for a quick flip but generational wealth as I believe it will fundamentally change oncology and the treatment of disease. I hope we can all remain patient as now would be the worst time for diehard longs to capitulate!
News 
Market Data 
Discover 
